Results from the long-term extension of the Phase III TRAILBLAZER-ALZ 2 trial (NCT04437511) showed sustained benefits with ...

Long-term extension data presented at the Alzheimer's Association International Conference showed amyloid plaque ...

Lilly’s Kisunla and Biogen/Eisai’s Leqembi can both continue to slow Alzheimer's cognitive decline after more than three ...

Eli Lilly (LLY) has recently shared positive developments in its innovative therapies, reporting significant progress with ...

The FDA greenlit multiple new drugs this month and issued some notable label expansions including for Eli Lilly’s Kisunla.

After beating quarterly earnings expectations and raising its full-year sales outlook from a previously forecast decline, ...

Findings from the TRAILBLAZER-ALZ 2 long-term extension study highlight Kisunla continued to demonstrate slowing of decline, with most participants having ...

The target is to reduce its workforce to less than 5,000 from a level of 5,800 at the end of 2024, said chief executive ...

A 61-year-old grandmother from New South Wales is among the first Australians to receive a newly approved medication for early Alzheimer's disease. The drug, called Kisunla or Donanemab, is the first ...